AGGF1 and prostate adenocarcinoma: In addition to known tumour occurrences (four fusions in melanoma, two fusions in prostate adenocarcinoma), we identified AGGF1–RAF1 fusions in seven papillary thyroid carcinoma samples (1.4%).